Community Practice Connections™: Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes – Reducing Cardiovascular Disease & CV Risk

CME: 1.5

Program Overview

Type 2 diabetes (T2D) and cardiovascular disease (CVD) share several risk factors as well as targeted treatment strategies. Although impaired glucose metabolism plays a central role in the pathology of CV complications in patients with T2D, several studies have demonstrated that CV risk cannot necessarily be reduced simply by achieving a therapeutic glucose goal. The focus on glucose control is shifting; it is expanding to include a comprehensive and ongoing assessment of patients’ CV risk.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the webcast Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes Regarding Cardiovascular Disease and CV Risk, held at the ASPC 2021 Internal Medicine meeting in July 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with T2D and CVD, putting recent trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current treatment guidelines for the reduction of CVD risk in patients with T2D
  • Evaluate the real-world evidence for reducing CV events and hospitalization to improve outcomes for patients with T2D
  • Apply emerging clinical data on issues concerning the treatment and prevention of CVD in patients with T2D

Post a comment to this article